Opportunities for improving therapy development in ALS.
In May 2013, The ALS Association and The Northeast ALS Consortium (NEALS) convened a meeting of stakeholders for a round-table discussion of ways to improve therapy development in ALS. The following overview summarizes issues raised and potential new directions discussed at the meeting. We recommend that future phase II clinical trials in ALS proceed when the proposed treatment is directed at targets that are likely to be involved in ALS pathogenesis in a defined subgroup of patients, and be accompanied by one or more biomarkers to track both clinical progression and pharmacodynamic engagement of the target. Innovations in trial structure and design, and greater involvement of patient advocates, may also improve trials.
ALS Association , Washington, D.C.
Lucie
L
Bruijn
Merit
M
Cudkowicz
D000690:Amyotrophic Lateral Sclerosis / Q000145:classification / Q000628:therapy*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D006801:Humans; D012107:Research Design
Amyotrophic lateral sclerosis; biomarkers; clinical trials; therapy